Report cover image

France Point-of-Care Glucose Testing Market By Product Type (Lancing Devices and Strips, Blood-Glucose Meter), By Application (Type-1 Diabetes, Type-2 Diabetes), By End User (Hospitals and Clinics, Home Care Settings, Others): Opportunity Analysis and Ind

Publisher Allied Market Research
Published Jun 02, 2023
Length 71 Pages
SKU # ALMR18790416

Description

France Point-of-Care Glucose Testing Market By Product Type (Lancing Devices and Strips, Blood-Glucose Meter), By Application (Type-1 Diabetes, Type-2 Diabetes), By End User (Hospitals and Clinics, Home Care Settings, Others): Opportunity Analysis and Industry Forecast, 2023-2032


The France point-of-care glucose testing market is witnessing significant traction in the market. This is attributed to rise in prevalence of type-1 as well as type-2 diabetes in the country. In addition, surge in diabetes cases has boosted the demand for glucose testing products, thereby driving the market growth. However, there are certain restraints of the market growth, including stringent regulatory framework governing the medical devices in France. Compliance with rigorous quality standards and clinical validation poses significant challenges for market players, particularly for new entrants, therefore hampering the market development. In addition, the dynamic reimbursement policies affect the affordability and accessibility of point-of-care glucose testing products, thus restraining the market.

On the contrary, the France point-of-care glucose testing market presents significant growth opportunities for market players. The integration of digital technology and data analytics into glucose testing devices is anticipated to open new avenues for growth. This integration offers real-time monitoring, data sharing, and remote healthcare management, thereby promising improved patient outcomes and healthcare efficiency. In addition, exploring the untapped areas of the market offers key players the opportunity to expand their geographical reach. Moreover, the aging population, coupled with changing lifestyles and dietary habits, is projected to expand the customer base of key players. The France point-of-care glucose testing market is projected to witness various trend in the future. One of the most prominent trends emerging in the market is increase in emphasis on noninvasive glucose monitoring technologies. Requisition for painless and user-friendly devices for glucose testing is expected to drive the demand for product innovation in the future. Furthermore, advanced sensors and wearables exhibit the potential to revolutionize the market.

The France point-of-care glucose testing market is segmented into product type, application, and end user. On the basis of product type, the market is bifurcated into lancing devices & strips and blood-glucose meters. As per application, the market is divided into type-1 diabetes and type-2 diabetes. According to end user segment, the market is classified into hospitals & clinics, home care settings, and others.

The various key players operating in the France point-of-care glucose testing market are Abbott, Roche Diagnostics, Arysta Lifescience, Lifescan, Sanofi, AgaMatrix, Nipro Diagnostics, Demeditec Diagnostics, Glucose Diagnostics and Acon Laboratories. Qualitative insights of the market depict the diverse perspectives and strategies of these key players. New product development is a key element of the market where the players strive to introduce novel solutions that offer precise glucose monitoring as well as enhance the overall user experience. In addition, R&D efforts are crucial to innovate the existing technologies and create next-generation glucose testing solutions. Furthermore, understanding end-user perceptions is essential to cater to the variable needs of consumers. Tailoring products and services to meet these distinct preferences requires a deep understanding of consumer behavior and healthcare dynamics. Moreover, pricing strategies are prominent for market players to strike the right balance between affordability and quality to remain competitive in the market. The price points of glucose testing products are influenced by factors such as manufacturing costs, competition, and reimbursement policies.

The Porter’s five forces analysis assists to understand the competitive scenario of the market and role of each stakeholder. The analysis includes threat of new entrants, threat of substitutes, bargaining power of buyers, bargaining power of suppliers, and competitive rivalry. The competitive rivalry among existing competitors is intense, with established players vying for market share and new entrants seeking to disrupt the conventionality of the market. The threat of new entrants is low as stringent regulations act as large barriers to entry. The bargaining power of suppliers is high, as the availability of quality raw materials and components directly impacts product quality. The bargaining power of buyers is high due to increase in awareness and boost in the number of alternatives available in the market. The threat of substitutes is significant as emerging technologies and alternative methods for glucose monitoring constantly challenge the relevance of traditional point-of-care testing solutions.

A SWOT analysis of the France point-of-care glucose testing market reveals a multitude of strengths, weaknesses, opportunities, and threats. Strengths of the market include its established network of healthcare providers, robust research ecosystem, and surge in awareness of diabetes management. However, weaknesses include complex regulatory landscape, pricing pressures, and ever-evolving reimbursement policies. On the contrary, opportunities for the market include integration of digital health solutions, catering to the aging population, and expansion into untapped markets. Contrarily, threats include technological disruptions, fluctuating market dynamics, and challenges of ensuring product quality & compliance in a highly regulated environment.

Key players operating in the France point-of-care glucose testing market include Abbott, Roche Diagnostics, Arysta Lifescience, Lifescan, Sanofi, AgaMatrix, Nipro Diagnostics, Demeditec Diagnostics, Glucose Diagnostics and Acon Laboratories.

Key Benefits For Stakeholders

Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.

Analyze the key strategies adopted by major market players in France point-of-care glucose testing market.

Assess and rank the top factors that are expected to affect the growth of France point-of-care glucose testing market.

Top Player positioning provides a clear understanding of the present position of market players.

Detailed analysis of the France point-of-care glucose testing market segmentation assists to determine the prevailing market opportunities.

Identify key investment pockets for various offerings in the market.
Product Benchmarking / Product specification and applications
Upcoming/New Entrant by Regions
New Product Development/ Product Matrix of Key Players
Patient/epidemiology data at country, region, global level
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By Product Type

Lancing Devices and Strips
Blood-Glucose Meter
Type
Lifescan OneTouch Ultra and Lifescan OneTouch Verio
Accu-Chek Aviva Plus and Accuchek
Freestyle Lite and Freestyle Precission Neo
Contour Next
Others

By Application

Type-1 Diabetes
Type-2 Diabetes

By End User

Hospitals and Clinics
Home Care Settings
Others

Key Market Players

Abbott
Roche Diagnostics
Arysta Lifescience
Lifescan
Sanofi
AgaMatrix
Nipro Diagnostics
Demeditec Diagnostics
Glucose Diagnostics
Acon Laboratories

Please Note: It will take 7-10 business days to complete the report upon order confirmation. 

Table of Contents

71 Pages
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.3. Porter’s Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market Size and Forecast, By Product Type
4.2. Lancing Devices and Strips
4.3. Blood-Glucose Meter
CHAPTER 5: FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market Size and Forecast, By Application
5.2. Type-1 Diabetes
5.3. Type-2 Diabetes
CHAPTER 6: FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER
6.1. Overview
6.1.1. Market Size and Forecast, By End User
6.2. Hospitals and Clinics
6.3. Home Care Settings
6.4. Others
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. Abbott
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. Roche Diagnostics
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Arysta Lifescience
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Lifescan
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Sanofi
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. AgaMatrix
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. Nipro Diagnostics
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Demeditec Diagnostics
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Glucose Diagnostics
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Acon Laboratories
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 02. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 03. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 04. ABBOTT: KEY EXECUTIVES
TABLE 05. ABBOTT: COMPANY SNAPSHOT
TABLE 06. ABBOTT: OPERATING SEGMENTS
TABLE 07. ABBOTT: PRODUCT PORTFOLIO
TABLE 08. ABBOTT: KEY STRATERGIES
TABLE 09. ROCHE DIAGNOSTICS: KEY EXECUTIVES
TABLE 10. ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 11. ROCHE DIAGNOSTICS: OPERATING SEGMENTS
TABLE 12. ROCHE DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 13. ROCHE DIAGNOSTICS: KEY STRATERGIES
TABLE 14. ARYSTA LIFESCIENCE: KEY EXECUTIVES
TABLE 15. ARYSTA LIFESCIENCE: COMPANY SNAPSHOT
TABLE 16. ARYSTA LIFESCIENCE: OPERATING SEGMENTS
TABLE 17. ARYSTA LIFESCIENCE: PRODUCT PORTFOLIO
TABLE 18. ARYSTA LIFESCIENCE: KEY STRATERGIES
TABLE 19. LIFESCAN: KEY EXECUTIVES
TABLE 20. LIFESCAN: COMPANY SNAPSHOT
TABLE 21. LIFESCAN: OPERATING SEGMENTS
TABLE 22. LIFESCAN: PRODUCT PORTFOLIO
TABLE 23. LIFESCAN: KEY STRATERGIES
TABLE 24. SANOFI: KEY EXECUTIVES
TABLE 25. SANOFI: COMPANY SNAPSHOT
TABLE 26. SANOFI: OPERATING SEGMENTS
TABLE 27. SANOFI: PRODUCT PORTFOLIO
TABLE 28. SANOFI: KEY STRATERGIES
TABLE 29. AGAMATRIX: KEY EXECUTIVES
TABLE 30. AGAMATRIX: COMPANY SNAPSHOT
TABLE 31. AGAMATRIX: OPERATING SEGMENTS
TABLE 32. AGAMATRIX: PRODUCT PORTFOLIO
TABLE 33. AGAMATRIX: KEY STRATERGIES
TABLE 34. NIPRO DIAGNOSTICS: KEY EXECUTIVES
TABLE 35. NIPRO DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 36. NIPRO DIAGNOSTICS: OPERATING SEGMENTS
TABLE 37. NIPRO DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 38. NIPRO DIAGNOSTICS: KEY STRATERGIES
TABLE 39. DEMEDITEC DIAGNOSTICS: KEY EXECUTIVES
TABLE 40. DEMEDITEC DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 41. DEMEDITEC DIAGNOSTICS: OPERATING SEGMENTS
TABLE 42. DEMEDITEC DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 43. DEMEDITEC DIAGNOSTICS: KEY STRATERGIES
TABLE 44. GLUCOSE DIAGNOSTICS: KEY EXECUTIVES
TABLE 45. GLUCOSE DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 46. GLUCOSE DIAGNOSTICS: OPERATING SEGMENTS
TABLE 47. GLUCOSE DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 48. GLUCOSE DIAGNOSTICS: KEY STRATERGIES
TABLE 49. ACON LABORATORIES: KEY EXECUTIVES
TABLE 50. ACON LABORATORIES: COMPANY SNAPSHOT
TABLE 51. ACON LABORATORIES: OPERATING SEGMENTS
TABLE 52. ACON LABORATORIES: PRODUCT PORTFOLIO
TABLE 53. ACON LABORATORIES: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET (2023-2032)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET
FIGURE 10. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET,BY PRODUCT TYPE, 2022 ($MILLION)
FIGURE 11. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET,BY APPLICATION, 2022 ($MILLION)
FIGURE 12. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET,BY END USER, 2022 ($MILLION)
FIGURE 13. TOP WINNING STRATEGIES, BY YEAR
FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 17. COMPETITIVE DASHBOARD
FIGURE 18. COMPETITIVE HEATMAP: FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET
FIGURE 19. TOP PLAYER POSITIONING, 2022
FIGURE 20. ABBOTT: NET SALES, 2020-2022* ($MILLION)
FIGURE 21. ABBOTT: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 22. ABBOTT: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 23. ROCHE DIAGNOSTICS: NET SALES, 2020-2022* ($MILLION)
FIGURE 24. ROCHE DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 25. ROCHE DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 26. ARYSTA LIFESCIENCE: NET SALES, 2020-2022* ($MILLION)
FIGURE 27. ARYSTA LIFESCIENCE: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 28. ARYSTA LIFESCIENCE: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 29. LIFESCAN: NET SALES, 2020-2022* ($MILLION)
FIGURE 30. LIFESCAN: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 31. LIFESCAN: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 32. SANOFI: NET SALES, 2020-2022* ($MILLION)
FIGURE 33. SANOFI: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 34. SANOFI: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 35. AGAMATRIX: NET SALES, 2020-2022* ($MILLION)
FIGURE 36. AGAMATRIX: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 37. AGAMATRIX: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 38. NIPRO DIAGNOSTICS: NET SALES, 2020-2022* ($MILLION)
FIGURE 39. NIPRO DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 40. NIPRO DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 41. DEMEDITEC DIAGNOSTICS: NET SALES, 2020-2022* ($MILLION)
FIGURE 42. DEMEDITEC DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 43. DEMEDITEC DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 44. GLUCOSE DIAGNOSTICS: NET SALES, 2020-2022* ($MILLION)
FIGURE 45. GLUCOSE DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 46. GLUCOSE DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 47. ACON LABORATORIES: NET SALES, 2020-2022* ($MILLION)
FIGURE 48. ACON LABORATORIES: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 49. ACON LABORATORIES: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us